NASDAQ:ADMP - Adamis Pharmaceuticals Stock Price, News, & Analysis Sign in or create an account to add this stock to your watchlist. Get Started $1.81 -0.09 (-4.74 %) (As of 05/20/2019 04:00 PM ET)Previous Close$1.90Today's Range$1.66 - $1.8652-Week Range$1.83 - $5.10Volume17,414 shsAverage Volume298,486 shsMarket Capitalization$85.59 millionP/E RatioN/ADividend YieldN/ABeta1.35 ProfileAnalyst RatingsChartEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesOptions ChainSEC FilingsSocial Media Share on FacebookShare on TwitterShare on LinkedInShare on RedditShare on StocktwitsPrint this articleShare by Email Adamis Pharmaceuticals Corporation, a specialty biopharmaceutical company, develops and commercializes products in the therapeutic areas of allergy and respiratory disease in the United States. The company's specialty pharmaceutical product candidates comprise Symjepi (epinephrine) Injection pre-filled syringe (PFS) for use in the emergency treatment of acute allergic reactions, including anaphylaxis. It also offers dry powder inhaler products consisting of albuterol (APC-2000) for the treatment of bronchospasms; fluticasone (APC-4000) for the treatment of asthma; beclomethasone (APC-1000), a metered dose inhaler product for the asthma; Tadalafil (APC-8000) for the treatment of erectile dysfunction; and naloxone injection product candidates (APC-6000) for the treatment of opioid overdose. In addition, the company provides corticosteroids, hormone replacement therapies, hospital outsourcing products, injectables, urological preparations, topical compounds for pain, and men's and women's health products; and certain veterinary pharmaceutical products for animals. Adamis Pharmaceuticals Corporation is headquartered in San Diego, California. Receive ADMP News and Ratings via Email Sign-up to receive the latest news and ratings for ADMP and its competitors with MarketBeat's FREE daily newsletter. Industry, Sector and Symbol Stock Exchange NASDAQ Industry Pharmaceutical preparations Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:ADMP Previous Symbol CUSIPN/A CIK887247 Webwww.adamispharmaceuticals.com Phone858-997-2400Debt Debt-to-Equity Ratio0.03 Current Ratio1.53 Quick Ratio1.95Price-To-Earnings Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/A Sales & Book Value Annual Sales$15.09 million Price / Sales5.67 Cash FlowN/A Price / Cash FlowN/A Book Value$0.84 per share Price / Book2.15Profitability EPS (Most Recent Fiscal Year)($1.00) Net Income$-39,010,000.00 Net Margins-239.53% Return on Equity-94.94% Return on Assets-73.03%Miscellaneous Employees152 Outstanding Shares47,290,000Market Cap$85.59 million Next Earnings Date8/9/2019 (Estimated) OptionableOptionable Adamis Pharmaceuticals (NASDAQ:ADMP) Frequently Asked Questions What is Adamis Pharmaceuticals' stock symbol? Adamis Pharmaceuticals trades on the NASDAQ under the ticker symbol "ADMP." How were Adamis Pharmaceuticals' earnings last quarter? Adamis Pharmaceuticals Corp (NASDAQ:ADMP) posted its earnings results on Thursday, May, 9th. The specialty pharmaceutical company reported ($0.19) earnings per share for the quarter, missing the Zacks' consensus estimate of ($0.15) by $0.04. The specialty pharmaceutical company had revenue of $4.91 million for the quarter, compared to analysts' expectations of $5.95 million. Adamis Pharmaceuticals had a negative return on equity of 94.94% and a negative net margin of 239.53%. View Adamis Pharmaceuticals' Earnings History. When is Adamis Pharmaceuticals' next earnings date? Adamis Pharmaceuticals is scheduled to release their next quarterly earnings announcement on Friday, August 9th 2019. View Earnings Estimates for Adamis Pharmaceuticals. What price target have analysts set for ADMP? 4 brokerages have issued twelve-month target prices for Adamis Pharmaceuticals' stock. Their forecasts range from $2.50 to $10.00. On average, they anticipate Adamis Pharmaceuticals' stock price to reach $5.8750 in the next year. This suggests a possible upside of 224.6% from the stock's current price. View Analyst Price Targets for Adamis Pharmaceuticals. What is the consensus analysts' recommendation for Adamis Pharmaceuticals? 4 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Adamis Pharmaceuticals in the last year. There are currently 1 hold rating and 3 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Adamis Pharmaceuticals. What are Wall Street analysts saying about Adamis Pharmaceuticals stock? Here are some recent quotes from research analysts about Adamis Pharmaceuticals stock: 1. According to Zacks Investment Research, "Adamis Pharmaceuticals Corporation, formerly Cellegy Pharmaceuticals, Inc., is a specialty pharmaceutical company engaged engages in the research, development, and commercialization of prescription medicines for the treatment of viral infections. Adamis Pharmaceuticals is composed of two wholly owned subsidiaries, Adamis Labs and Adamis Viral Therapies. Adamis Labs is a commercial stage specialty pharmaceutical company targeting high-prescribing physicians in the allergy, respiratory and pediatric medicine market segments. To complement and add to the sales efforts of Adamis Labs, Adamis Viral Therapies is focused on the development of patented, highly-valued proprietary vaccine technology that Adamis believes has the potential to prevent or treat infections such as influenza or chronic hepatitis. Adamis also provides packaging for pharmaceutical and nutraceutical products. The company is headquartered in Del Mar, California. " (1/14/2019) 2. Maxim Group analysts commented, "The PDUFA date for Symjepi jr. (0.15mg) is approaching on 9/27/18, we expect a positive response from the FDA. Symjepi (0.3mg & 0.15mg) is partnered to Sandoz-Novartis (NVS – NR). Our expectation is that Sandoz will launch both Symjepi products sometime in the second half following low-dose approval (though precise timing has not been announced)." (9/12/2018) 3. HC Wainwright analysts commented, "EpiPen as an Exchange NASDAQ Value (M) $65.4 Market Cap (M) $101 Shares Outstanding (M) 45.1 3 Interest (M) 3.55 Cash (M) $37.9 Total Debt (M) $2.3 Cash balances and share count are projected based on 3Q18 capital raise." (8/23/2018) Has Adamis Pharmaceuticals been receiving favorable news coverage? News headlines about ADMP stock have been trending somewhat negative on Monday, according to InfoTrie Sentiment Analysis. The research firm scores the sentiment of news coverage by analyzing more than six thousand blog and news sources. The firm ranks coverage of public companies on a scale of -5 to 5, with scores closest to five being the most favorable. Adamis Pharmaceuticals earned a media sentiment score of -1.0 on InfoTrie's scale. They also assigned media headlines about the specialty pharmaceutical company a news buzz of 10.0 out of 10, meaning that recent news coverage is extremely likely to have an effect on the company's share price in the immediate future. Who are some of Adamis Pharmaceuticals' key competitors? Some companies that are related to Adamis Pharmaceuticals include Theratechnologies (THERF), Rigel Pharmaceuticals (RIGL), AMAG Pharmaceuticals (AMAG), Keryx Biopharmaceuticals (KERX), AC Immune (ACIU), Beyondspring (BYSI), XBiotech (XBIT), Xeris Pharmaceuticals (XERS), Five Prime Therapeutics (FPRX), BIOFRONTERA AG/ADR (BFRA), Merus (MRUS), Zynerba Pharmaceuticals (ZYNE), Kindred Biosciences (KIN), Neptune Wellness Solutions (NEPT) and ImmunoGen (IMGN). What other stocks do shareholders of Adamis Pharmaceuticals own? Based on aggregate information from My MarketBeat watchlists, some companies that other Adamis Pharmaceuticals investors own include Synergy Pharmaceuticals (SGYP), Progenics Pharmaceuticals (PGNX), Trevena (TRVN), Viking Therapeutics (VKTX), Verastem (VSTM), Exelixis (EXEL), Sorrento Therapeutics (SRNE), BioDelivery Sciences International (BDSI), Corbus Pharmaceuticals (CRBP) and Novavax (NVAX). Who are Adamis Pharmaceuticals' key executives? Adamis Pharmaceuticals' management team includes the folowing people: Mr. Richard C. Williams, Chairman & Consultant (Age 75)Dr. Dennis J. Carlo, Pres, CEO & Director (Age 76)Mr. Robert O. Hopkins, VP of Fin., CFO & Sec. (Age 59)Mr. David J. Marguglio, Sr. VP, Chief Bus. Officer & Director (Age 49)Mr. Robert B. Rothermel, Consultant & Director (Age 75) Who are Adamis Pharmaceuticals' major shareholders? Adamis Pharmaceuticals' stock is owned by a number of of institutional and retail investors. Top institutional investors include First Manhattan Co. (7.09%), DekaBank Deutsche Girozentrale (2.54%), BlackRock Inc. (2.01%), Morgan Stanley (0.55%), Leisure Capital Management (0.24%) and Northern Trust Corp (0.19%). Company insiders that own Adamis Pharmaceuticals stock include David J Marguglio, Dennis J Phd Carlo, Karen K Daniels, Robert O Hopkins and Ronald B Moss. View Institutional Ownership Trends for Adamis Pharmaceuticals. Which institutional investors are selling Adamis Pharmaceuticals stock? ADMP stock was sold by a variety of institutional investors in the last quarter, including Northern Trust Corp, First Manhattan Co. and BlackRock Inc.. Company insiders that have sold Adamis Pharmaceuticals company stock in the last year include David J Marguglio, Dennis J Phd Carlo, Karen K Daniels, Robert O Hopkins and Ronald B Moss. View Insider Buying and Selling for Adamis Pharmaceuticals. Which institutional investors are buying Adamis Pharmaceuticals stock? ADMP stock was acquired by a variety of institutional investors in the last quarter, including DekaBank Deutsche Girozentrale, Morgan Stanley, ExodusPoint Capital Management LP, BlueCrest Capital Management Ltd, Virtu Financial LLC, Wedbush Securities Inc., Charles Schwab Investment Management Inc. and Jefferies Group LLC. View Insider Buying and Selling for Adamis Pharmaceuticals. How do I buy shares of Adamis Pharmaceuticals? Shares of ADMP can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab. What is Adamis Pharmaceuticals' stock price today? One share of ADMP stock can currently be purchased for approximately $1.81. How big of a company is Adamis Pharmaceuticals? Adamis Pharmaceuticals has a market capitalization of $85.59 million and generates $15.09 million in revenue each year. The specialty pharmaceutical company earns $-39,010,000.00 in net income (profit) each year or ($1.00) on an earnings per share basis. Adamis Pharmaceuticals employs 152 workers across the globe. What is Adamis Pharmaceuticals' official website? The official website for Adamis Pharmaceuticals is http://www.adamispharmaceuticals.com. How can I contact Adamis Pharmaceuticals? Adamis Pharmaceuticals' mailing address is 11682 EL CAMINO REAL SUITE 300, SAN DIEGO CA, 92130. The specialty pharmaceutical company can be reached via phone at 858-997-2400 or via email at [email protected] MarketBeat Community Rating for Adamis Pharmaceuticals (NASDAQ ADMP)Community Ranking: 3.3 out of 5 ( )Outperform Votes: 259 (Vote Outperform)Underperform Votes: 136 (Vote Underperform)Total Votes: 395MarketBeat's community ratings are surveys of what our community members think about Adamis Pharmaceuticals and other stocks. Vote "Outperform" if you believe ADMP will outperform the S&P 500 over the long term. Vote "Underperform" if you believe ADMP will underperform the S&P 500 over the long term. You may vote once every thirty days. This page was last updated on 5/20/2019 by MarketBeat.com StaffFeatured Article: How to interpret the current ratio Receive Analysts' Upgrades and Downgrades Daily Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.